ClinicalTrials.gg
Active, not recruitingNCT06709144BLARCCUpdated Nov 29, 2024

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

A Phase 3 interventional study of SMA lymph node dissection and SMV lymph node dissection in Colon Cancer, sponsored by Haixing Ju, MD. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Haixing Ju, MD · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
896
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 211 studies in Colonic Neoplasms with a site in China — 101 open to participants now, 117 under way, 22 of them phase 3. Colonic Neoplasms · China.

Planned enrollment
17th of 163
896 · median 110
Started
2024
with 26 others
Phase 3
28 of 211
15 open now
Primary completion
2027-06
later than 71 of 116 live
Registered
162nd of 211
by date

Among the 211 studies in Colonic Neoplasms with a site in China, this one is the 17th largest by planned enrollment of the 163 interventional ones that give a count, is one of 27 that started in 2024, is one of 28 in phase 3, reaches primary completion later than 71 of the 116 other live ones, and was the 162nd registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

101 of the 211 studies in Colonic Neoplasms with a site in China are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Colonic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The study was conducted on patients with advanced right-sided colon cancer, and the clinical pathological and prognostic data of the patients were compared between the two groups of patients who were randomly divided into those undergoing SMV and SMA left resection, with the aim of resolving the controversy over the left resection boundary of CME/D3 lymph node dissection through this study, and to clarify whether SMA left resection is superior to SMV left resection.

03

Conditions studied

  • Colon Cancer

Browse trials for

Keywords

  • right side colon cancer
  • complete mesentery resection
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • right side colon cancer(The primary lesion is located in the ileocecal region, ascending colon, hepatic flexure of colon, or proximal transverse colon)
  • T3-4 and/or N1-2M0
  • Colonoscopy and pathological confirmed colon adenocarcinoma

Exclusion criteria

Exclusion Criteria:

  • T1-2N0M0
  • Cannot undergo curative resection
  • Simultaneous multiple primary colorectal cancer or other diseases requiring segmental resection
  • Distant
  • Tumor invades surrounding organs, requiring joint organ resection
  • Emergency surgery is required for complications such as intestinal obstruction, perforation, and bleeding
  • Patients who have received therapy before surgery
  • Pregnant or lactating women
  • Patients who are not suitable or unable to tolerate surgery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
896 participants (estimated)

Study arms

  • Experimental
    Group SMA

    The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA).

    Procedure: SMA lymph node dissection

  • Active comparator
    Group SMV

    The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)

    Procedure: SMV lymph node dissection

Interventions

  • ProcedureSMA lymph node dissection

    The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)

  • ProcedureSMV lymph node dissection

    The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)

06

What researchers measure

Primary outcomes

  1. 3 year DFS

    3 year disease free survival

    Time frame: 3 years

Secondary outcomes

  1. 5 year OS

    5 year Overall survival

    Time frame: 5 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.

Of 55 non-industry phase 3 interventional studies under Colonic Neoplasms, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 123. This study's planned 35 months is below that.

Counting every sponsor, half of 72 studies reached it within 55 months; a quarter within 37 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 29, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2032
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06709144
Lead sponsor
Haixing Ju, MD
Collaborators
Jiangxi Provincial Cancer Hospital, Jiangsu Cancer Institute & Hospital, Liaoning Cancer Hospital & Institute, The First Affiliated Hospital of Soochow University, Shanxi Province Cancer Hospital, The First Affiliated Hospital of Shanxi Medical University, Shaoxing People's Hospital, Shaoxing Second Hospital, Ningbo No. 1 Hospital, Ningbo No.2 Hospital, Jinhua Central Hospital, Affiliated Hospital of Jiaxing University, The First People's Hospital of Huzhou, The Central Hospital of Lishui City, Lishui Country People's Hospital, Shengzhou People's Hospital, Yuyao People's Hospital, Rui'an People's hospital, First Affiliated Hospital of Wenzhou Medical University, Cancer Hospital of Guangxi Medical University, Ningbo Medical Center Lihuili Hospital, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Second Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Cancer Hospital, China, The Affiliated Tumor Hospital of Harbin Medical University, Shanghai 10th People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Xiangshan No.1 People' s Hospital, Zhejiang Province People's Hospital, Sir Run Run Shaw Hospital, Sun Yat-sen University Cancer Hosptial
Responsible party
Haixing Ju, MD (Director, Zhejiang Cancer Hospital) — Sponsor-investigator
First posted
Nov 29, 2024
Start date
Jul 1, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2032 (estimated)
Last update
Nov 29, 2024

Study contacts

Haixing Ju
principal investigator · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion